Siemens Healthineers Raises 2022 Outlook Thanks to Covid-19 Tests
03 Februar 2022 - 07:50AM
Dow Jones News
By Cristina Roca
Siemens Healthineers AG said Thursday that its first-quarter
revenue and earnings rose, and upgraded its guidance for fiscal
2022 as it expects to generate more revenue from its rapid Covid-19
antigen tests.
The German medical-equipment maker said net income was 472
million euros ($533.6 million) in the quarter ended Dec. 31 up from
EUR437 million a year earlier.
Revenue was EUR5.07 billion, up 9.5% on year on a comparable
basis, the company said. Analysts had expected the company to post
quarterly revenue of EUR4.93 billion, according to a FactSet
consensus.
Excluding rapid Covid-19 antigen tests, revenue rose 4.5%.
Siemens Healthineers said it now expects the tests to generate
around EUR700 million in revenue, compared with previous
expectations of EUR200 million, in fiscal 2022.
As a result, it raised its annual comparable revenue growth
guidance to 3% to 5%, from 0%-2% previously, and its targeted
adjusted basic earnings per share to EUR2.18-EUR2.30, from
EUR2.08-EUR2.20 previously.
Write to Cristina Roca at cristina.roca@wsj.com
(END) Dow Jones Newswires
February 03, 2022 01:35 ET (06:35 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Siemens Healthineers (TG:SHL)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Siemens Healthineers (TG:SHL)
Historical Stock Chart
Von Mär 2023 bis Mär 2024